VALUE-Dx

@IMI_JU project uniting 6 in vitro diagnostic companies with 20 non-industry partners to combat #AMR through #diagnostics to improve outcomes for patients

[VALUE-Dx @ValueDx]

VALUE-Dx may have ended, but its impact lives on! Thanks to the European Respiratory Society @EuroRespSoc, all educational materials & project resources remain freely accessible on their virtual learning hub. Discover more here ⬇️ https://t.co/AZDn1RXVbX
#AMR #diagnostics

[VALUE-Dx @ValueDx]

Our new study highlights how funding & pricing policies can boost #POCTs adoption to improve antibiotic prescribing & combat #AMR. Tailored policy recommendations for CA-ARTI POCTs could reshape health systems across Europe? Read the paper here ➡️ https://t.co/p28GDOmYut

[VALUE-Dx @ValueDx]

VALUE-Dx project lead & coordinator Em. Prof. @ProfHGoossens shares the project’s origin, reflects on unexpected challenges brought by the #COVID19 pandemic, gives his perspective on the future of rapid diagnostic tests & more. Watch the interview here ⬇️ https://t.co/LVfZtwnYCn

[VALUE-Dx @ValueDx]

Congratulations to the authors! @hoste_melanie @BorekAleksandra @MartaSantillo Nia Roberts @SKGTonkinCrine @sibylanthierens

[VALUE-Dx @ValueDx]

New publication! A systematic review explores healthcare professionals' & patients' views on using #POCTs for managing #RTIs in primary care, recommending multi-level interventions to ensure effective implementation. Read the study here ⬇️ https://t.co/OOBKqkIqY8 @BSACandJAC

[VALUE-Dx @ValueDx]

Exciting advancements in diagnosing community-acquired #ARTI's! VALUE-Dx has developed an innovative clinical algorithm that improves accuracy & efficiency by integrating multiple diagnostic tests & clinical data. Learn more here ⬇️ https://t.co/MvkuNSYLSF #diagnostics

[VALUE-Dx @ValueDx]

In Sept, VALUE-Dx celebrated 5.5 years of impactful research at a Closing Conference in Valencia! Over 80 experts shared key findings, incl. advancements in diagnosing #CARTI's & insights from the clinical studies. Read more in our recap here ➡️ https://t.co/ArcqnuDUGi #AMR

[VALUE-Dx @ValueDx]

It's the second & last day of the VALUE-Dx Closing Conference! Here's a reminder to tune into our final panel discussion at 11:20 CET to learn more about the role of rapid diagnostics for CA-LRTI. Join here ➡️ https://t.co/4Ot40If1KS #AMR #diagnostics #ClinicalTrials

[VALUE-Dx @ValueDx]

Don’t miss the final panel discussion at the VALUE-Dx Closing Conference! 📢 Join us on 5 Sept at 11:20h CET as experts dive into the latest insights from the ADEQUATE & PRUDENCE studies on rapid diagnostics for CA-LRTI. Tune in via our website here ⬇️ https://t.co/D94G2Ie6fk

[VALUE-Dx @ValueDx]

The day has arrived, we’re kicking off our Closing Conference! On the agenda today are talks on the clinical algorithm, user requirement specs & interoperability networks for #AMR clinical research. We’ll also deep dive into the PRUDENCE & ADEQUATE clinical trials. #diagnostics

[VALUE-Dx @ValueDx]

Don’t miss the final panel discussion at the VALUE-Dx Closing Conference! 📢 Join us on 5 Sept at 11:20h CET as experts dive into the latest insights from the ADEQUATE & PRUDENCE studies on rapid diagnostics for CA-LRTI. Tune in via our website here ⬇️ https://t.co/D94G2Ie6fk

[VALUE-Dx @ValueDx]

The countdown has begun! Only 2 weeks left until our VALUE-Dx Closing Conference in Valencia, where we will discuss in detail the final project results and look back on our journey. We’ll be streaming the event, so you can attend the sessions virtually via https://t.co/4Ot40If1KS

[VALUE-Dx @ValueDx]

We interviewed Dr. Arjana Tambic Andrasevic, leading Croatian expert on antimicrobial resistance! Dr. Tambic shares her insights on the challenges of #AMR, the importance of robust surveillance, and the critical role of rapid #diagnostics. Read it here ⬇️ https://t.co/uFf4vqgKix

[VALUE-Dx @ValueDx]

To honour the nearing end of the VALUE-Dx project, we are hosting a closing conference on 4-5 Sept. During the event, we'll look back on the tremendous journey, discuss final results & the possible continuation of the work. Find out more here ➡️ https://t.co/D94G2Ie6fk #AMR

[VALUE-Dx @ValueDx]

During #ESCMIDGlobal2024 VALUE-Dx hosted a symposium on the crucial topic of managing lower respiratory tract infections. You can now rewatch the symposium on the @EuroRespSoc Virtual Learning Platform ➡️ https://t.co/TLfCq3Veai #AMR

[VALUE-Dx @ValueDx]

On 10 Sept, we're hosting a symposium during the @EuroRespSoc congress. The topic is the value of in-vitro diagnostic tests to reduce #AMR & improve patient outcomes. You can attend the session online or onsite in Vienna. Find out more ➡️ https://t.co/TQEk4oZCrZ #diagnostics

[ERS @EuroRespSoc]

🌍 The ERS Congress 2024
��� Vienna, Austria & online
📆 7–11 September

Registration is open for the #ERSCongress 2024. Join us for the early-bird discounted fee by registering by 3 July – book your place online: https://t.co/ksCIQstgxX

[VALUE-Dx @ValueDx]

Study update! Recruitment for ADEQUATE-paediatric & PRUDENCE wrapped up in Jan 2024. The focus now shifts to a comprehensive phase involving data cleansing, microbiological investigations, & health-economic modelling. Read more here ➡️ https://t.co/SYF66aAGw0 #AMR #diagnostics

[VALUE-Dx @ValueDx]

At 8:30 CEST the Value-Dx symposium on mgt of lower resp tract infections runs at #ESCMIDGlobal in Hall H. Simon van der Pol addresses health technology assessment of diagnostic strategies, @EvaPolverino discusses colonisation or infection in patients with chronic resp diseases!

[Till Bachmann @BachmannTill]

Again, could not agree more. Innovation in #AMR #diagnostics should be patient centric. @SMalhotraKumar #ESCMIDGlobal2024 @ESCMID @ValueDx

[VALUE-Dx @ValueDx]

Dr. Füsun Can leads a multidisciplinary team focused on #AMR research in Istanbul. They aim to tackle emerging infectious diseases across Turkey. Read the full interview to learn more about their impactful efforts & combatting #AMR together ⬇️ https://t.co/Ba1Mr5jyd6

[VALUE-Dx @ValueDx]

Read our paper on barriers & facilitators in pricing/funding policies of EU countries, impacting the use of point-of-care diagnostics for acute respiratory infections. Identified barriers include lack of diagnostics evidence & absence of price regulation: https://t.co/DOZw2tFLNx